Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ERYTECH Pharma S A : to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

09/15/2021 | 04:05pm EDT


ERYTECH to Host on September 21, 2021
Second Quarter 2021 conference call and Business Update

<hr />

Lyon (France) and Cambridge, MA (U.S.), September 15, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2021 conference call and webcast on Tuesday, September 21, 2021, at 2:30 PM CEST/8:30 AM ET to discuss operational highlights.


The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6866536 (Conference ID : 6866536)
Once registered, participants will receive a unique access code and the call number details to join the teleconference.

The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/z2wjhmw4.

An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 6866536#.

An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com


About ERYTECH

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out final results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.        

For more information, please visit www.erytech.com        

CONTACTS
  

ERYTECH                     
Eric Soyer
CFO & COO
LifeSci Advisors, LLC
Corey Davis, Ph.D.
Investor Relations

NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations


+33 4 78 74 44 38
investors@ERYTECH.com


+1 (212) 915 - 2577
cdavis@lifesciadvisors.com


+33 1 44 71 94 94
ERYTECH@newcap.eu


Attachment

  • ERYTECH_PR_2021_H1_Ccall-announcement_EN

© OMX, source GlobeNewswire - EU Press Releases

All news about ERYTECH PHARMA S.A.
06:06aJMP Securities Downgrades ERYTECH Pharma to Market Perform From Market Outperform
MT
06:05aCowen Downgrades ERYTECH Pharma to Market Perform From Outperform
MT
10/25NASDAQ 100 : Top Midday Decliners
MT
10/25European ADRs Move Lower in Monday Trading
MT
10/25ERYTECH PHARMA S A : ▪The prespecified subgroup of patients treated with eryaspase a..
PU
10/25GLOBAL MARKETS LIVE : HSBC, PayPal, Tesla, Daimler, Intel...
10/25Wall Street Sees Cautiously Higher Open Ahead of Busy Week for Tech Earnings; FB Earnin..
MT
10/25Health Care Stocks Mixed Premarket Monday
MT
10/25ERYTECH PHARMA S A : Health Care
MT
10/25Top Premarket Decliners
MT
More news
Analyst Recommendations on ERYTECH PHARMA S.A.
More recommendations
Financials
Sales 2021 7,95 M 9,22 M 9,22 M
Net income 2021 -63,0 M -73,1 M -73,1 M
Net Debt 2021 16,1 M 18,7 M 18,7 M
P/E ratio 2021 -0,72x
Yield 2021 -
Capitalization 78,7 M 91,3 M 91,3 M
EV / Sales 2021 11,9x
EV / Sales 2022 5,89x
Nbr of Employees 196
Free-Float 67,5%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 2,82 €
Average target price 12,40 €
Spread / Average Target 340%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-60.34%102
GILEAD SCIENCES, INC.16.25%84 845
BIONTECH SE258.67%71 229
WUXI APPTEC CO., LTD.23.63%64 399
REGENERON PHARMACEUTICALS22.57%59 906
VERTEX PHARMACEUTICALS-22.12%47 992